Asunto(s)
Servicios de Información sobre Medicamentos/organización & administración , Salud Global , Investigación sobre Servicios de Salud/organización & administración , Trastornos Mentales/tratamiento farmacológico , Psicotrópicos/uso terapéutico , Academias e Institutos/organización & administración , Humanos , Cooperación Internacional , Trastornos Mentales/prevención & control , Organización Mundial de la SaludAsunto(s)
Estado de Salud , Salud , Adolescente , Adulto , Factores de Edad , Anciano , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Factores Sexuales , España , Estadísticas VitalesRESUMEN
A total of 370 patients were subjected to a comprehensive international examination (within the frameworks of the WHO) by the double blind method for the efficacy of low (75 mg/day) and high (150 mg/day) doses of antidepressants (maprotiline, amitriptyline, imipramine). In 324 patients, the time course of the psychopathological disorders and side effects was studied with the aid of special scales and maps. The selection of the population and, therefore, the selection of the 7 cooperative WHO centers was based on the necessity of the maximal coverage of possible cultural, economic and ethnic relations in the patients' populations. Analysis of the total appraised ratios obtained in the course of 3 examinations of the patients has shown definite differences in the efficacy of high and low doses of the drugs under study. The data obtained indicate that the therapeutic response was equal whatever the dose (in the developing and Asian countries). In the developed countries, high doses of the drugs were found to be more effective than low ones.
Asunto(s)
Antidepresivos/uso terapéutico , Antidepresivos/administración & dosificación , Antidepresivos/efectos adversos , Características Culturales , Trastorno Depresivo/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Etnicidad , Humanos , Cooperación Internacional , Proyectos de Investigación , Factores de TiempoAsunto(s)
Trastornos Mentales/tratamiento farmacológico , Psicotrópicos/uso terapéutico , Ensayos Clínicos como Asunto , Costos y Análisis de Costo , Países en Desarrollo , Relación Dosis-Respuesta a Droga , Utilización de Medicamentos , Humanos , Psicotrópicos/efectos adversos , Organización Mundial de la SaludRESUMEN
Different preventive approaches of mental and neurological disorders are discussed. Special emphasis has been put on the advances of biological research in the elucidation of aetiological and pathogenic mechanisms of major psychoses, such as schizophrenia and affective disorders. Perspectives of genetic and psychopharmacological research are emphasized. Multidisciplinary efforts are needed for the improvement of existing preventive measures.